Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The UK regulator MHRA announced on 26 June that it would again permit recruitment to the COPCOV COVID-19 prevention clinical trial. The MHRA decision came 5 weeks after it reacted immediately to the now-discredited paper published in The Lancet suggesting harms with hydroxychloroquine, and paused recruitment of UK participants. But The Lancet paper was based on fabricated data and was swiftly retracted. After this interruption, recruitment around the globe to COPCOV can now resume.

Hand holding pills © 2020 MORU. Photographer: Supa-at Asarath.
Load More

Similar stories

Behind the Title: Becoming an Oxford Professor (at NDM), featuring Professor Phaik Yeong Cheah

The Behind the Title: Becoming an Oxford Professor (at NDM) series highlights the diverse journeys of our professors and the many paths that lead to academic leadership. By sharing their journeys we aim to showcase the breadth of backgrounds, disciplines, and experiences represented across the Department, demonstrating that there is no single route to becoming a professor at Oxford. In our first feature, we hear from Professor Phaik Yeong Cheah, Head of Bioethics and Engagement at the Mahidol Oxford Tropical Medicine Research Unit (MORU), Nuffield Department of Medicine, based in Bangkok.